Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes

Novo Nordisk A/S2,223 enrolled

Overview

This study is conducted in Europe. The aim of this study is to evaluate the safety and efficacy of biphasic insulin aspart (NovoMix® 30) in hospitalised patients with type 2 diabetes with the aim of intensifying their treatment.

Study Type

OBSERVATIONAL

Enrollment

2,223

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 30DRUG

Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with type 2 diabetes * Treated with oral anti-diabetics and/or human insulin Exclusion Criteria: * Persons previously included in the trial * Hypersensitive to biphasic insulin aspart or any of the excipients * Pregnant or lactating women, or those who plan to get pregnant within the next 12 months

Locations (1)

Novo Nordisk Investigational Site

Warsaw, Poland

Outcomes

Primary Outcomes

Frequency of severe hypoglycaemic episodes

Secondary Outcomes

Number of severe hypoglycaemic episodes

Number of mild hypoglycaemic episodes

Postprandial glucose concentration after breakfast, lunch, and dinner

Average fasting glucose concentration after waking and before main meals

Average plasma glucose level at bedtime and at night

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.